Clinical Trials Logo

Clinical Trial Summary

Prospective, non-interventional, feasibility study. 8 months, from start of screening to finishing the study. Multi-center study, with a maximum of 8 centers in Europe. Health adult volunteers (21 years or older) and adult patients with a clinical indication for ambulatory outpatient cardiac monitoring. To observe the feasibility of remotely monitoring patients with the novel µCor Heart Failure and Arrhythmia Management System (µCor system ) that non-invasively captures thoracic fluid content, electrocardiogram, heart rate, respiratory rate, activity, and body posture. tory outpatient cardiac monitoring.


Clinical Trial Description

The study will consist of two phases. Phase I of the study will enroll 6 healthy volunteers, who have no indication for remote cardiac monitoring. Subjects are required to participate in the study for 30 days. Phase II of the study will enroll up to 44 patients indicated for outpatient cardiac monitoring and will participate in the study for up to 90 days. All subjects will wear the device in two locations, one along the left midaxillary line and the other along the left midclavicular line for the first seven days. Thereafter, for the remainder of the study, half the enrolled subjects will only wear the device in the left midclavicular position and the other half will wear the device in the left midaxillary position. Subjects will use a diary to keep a daily log their activities of daily living (phase I) or a log of any symptoms related to heart rhythm abnormalities and heart failure (phase II). Data will be acquired with the µCor system and wirelessly transmitted daily to a remote server for processing, generating thoracic fluid content, ECG, heart rate, respiration rate, activity, and posture measurements. Investigators will have access only to ECG data. Study staff will make weekly phone calls to subjects and record any new clinically actionable events. Patients will have monthly office visits. At the end of 30 days (phase I) or 90 days (phase II), patients will end wear and will complete the study follow-up questionnaire. The study will enroll a maximum of 50 subjects. Six healthy volunteers will be enrolled for phase I of the study. Remaining 44 subjects will be enrolled for phase II and will have an indication of outpatient cardiac monitoring. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04512703
Study type Observational [Patient Registry]
Source Zoll Medical Corporation
Contact
Status Completed
Phase
Start date October 25, 2018
Completion date August 2, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Active, not recruiting NCT04254731 - Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals Phase 4
Recruiting NCT04833712 - Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation N/A
Completed NCT05966922 - Transcutaneous Electrical Stimulation & Sinoatrial Node Function N/A
Recruiting NCT06324682 - ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing
Recruiting NCT05239364 - Ablation of Consecutive Atrial Tachycardia N/A